Generic pharma and companies interested in new uses for old drugs alike include skinny labels – labels which do not recite uses for the drug that remain covered by a competitor’s patent – as part of their intellectual...more
The Court of Appeals for the Federal Circuit reconsiders its previous decision on the availability of judicial review of IPRs.
The statutes, namely 35 U.S.C. §§ 314(d) and 315(b), governing institution of inter partes...more
In 2014, the Supreme Court’s opinion in Petrella v. Metro-Goldwyn-Mayer, Inc. held that the equitable doctrine of laches is not available as a defense to copyright infringement when the claim is brought within the three years...more
The U.S. Supreme Court’s opinion in Life Technologies Corp. v. Promega Corp., No. 14-1538, (February 22, 2017), interpreted 35 U.S.C. § 271(f)(1), which creates liability for supplying components of multi-component patented...more